Methods for the treatment of substance abuse
OwnerAlbert Shulmaninventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of therapy for substance addiction comprising the administration to a subject in need thereof a combination of: (i) a μ-opioid receptor antagonist; (ii) a calcium channel blocker which is long-acting or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator; as well as combinations, kits and composition useful therefor.
Claims37
A method of treating substance addiction in a subject in need thereof, which method comprises administering to said subject a combination of:
- (i) a μ-opioid receptor antagonist (μORA);
- (ii) a calcium channel blocker (CCB) which is long-acting or in sustained-release form, or which is nimodipine in rapid release form;
- and
- (iii) an NMDA glutamate receptor modulator.
Use of a μORA in the preparation of a medicament for the treatment of substance addiction, wherein said medicament is adapted for administration to a subject in combination with an NMDA glutamate receptor modulator and a CCB, which is long-acting or in sustained-release form or which is nimodipine in rapid release form.
Use of a CCB which is long-acting or in sustained-release form, or which is nimodipine in rapid release form, in the preparation of a medicament for the treatment of substance addiction, wherein said medicament is adapted for administration in combination with a μORA and an NMDA glutamate receptor modulator.
Use of an NMDA glutamate receptor modulator in the preparation of a medicament for the treatment of substance addiction where said medicament is adapted for administration in combination with a CCB, which is long-acting or in sustained-release form, or which is nimodipine in rapid release form, and a μORA.
Use of a μORA, an NMDA glutamate receptor modulator and a CCB in the preparation of a medicament for the treatment of substance addiction, wherein the CCB is long-acting or formulated in the medicament such that it is in a sustained-release form or is nimodipine in rapid release form.
Dependencies are inferred from the claim text.